Kobayashi Pharmaceutical Co Ltd
TSE:4967

Watchlist Manager
Kobayashi Pharmaceutical Co Ltd Logo
Kobayashi Pharmaceutical Co Ltd
TSE:4967
Watchlist
Price: 5 842 JPY -0.97% Market Closed
Market Cap: ¥434.3B

EV/EBITDA

15.4
Current
27%
More Expensive
vs 3-y average of 12.1

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
15.4
=
Enterprise Value
¥370.2B
/
EBITDA
¥23.7B

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
15.4
=
Enterprise Value
¥370.2B
/
EBITDA
¥23.7B

Valuation Scenarios

Kobayashi Pharmaceutical Co Ltd is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (12.1), the stock would be worth ¥4 595.56 (21% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-44%
Maximum Upside
No Upside Scenarios
Average Downside
28%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 15.4 ¥5 842
0%
3-Year Average 12.1 ¥4 595.56
-21%
5-Year Average 15.1 ¥5 753.31
-2%
Industry Average 8.7 ¥3 286.92
-44%
Country Average 8.7 ¥3 290.97
-44%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
¥370.2B
/
Jan 2026
¥23.7B
=
15.4
Current
¥370.2B
/
Dec 2026
¥24.7B
=
15
Forward
¥370.2B
/
Dec 2027
¥28.8B
=
12.9
Forward
¥370.2B
/
Dec 2028
¥33.4B
=
11.1
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
JP
Kobayashi Pharmaceutical Co Ltd
TSE:4967
434.3B JPY 15.4 118.8
FR
L'Oreal SA
PAR:OR
184.2B EUR 17.1 30.1
UK
Unilever PLC
LSE:ULVR
92B GBP 11.3 11.2
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
5.2T INR 35.8 37.2
UK
HALEON PLC
LSE:HLN
31.4B GBP 13.2 18.8
US
Estee Lauder Companies Inc
NYSE:EL
27.4B USD 14.3 -154.1
DE
Beiersdorf AG
XETRA:BEI
16.4B EUR 8.2 17.4
JP
Kao Corp
TSE:4452
2.7T JPY 10 22.6
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
1.1T INR 37.3 62
CA
Relevium Technologies Inc
XTSX:RLV
12.2B CAD -6 373.4 -4 624.4
IN
Dabur India Ltd
NSE:DABUR
783.4B INR 31.5 43.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Kobayashi Pharmaceutical Co Ltd
TSE:4967
Average EV/EBITDA: 19.4
15.4
12%
1.3
FR
L'Oreal SA
PAR:OR
17.1
7%
2.4
UK
Unilever PLC
LSE:ULVR
11.3
4%
2.8
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
35.8
7%
5.1
UK
HALEON PLC
LSE:HLN
13.2
7%
1.9
US
Estee Lauder Companies Inc
NYSE:EL
14.3
16%
0.9
DE
Beiersdorf AG
XETRA:BEI
8.2
3%
2.7
JP
Kao Corp
TSE:4452
10
7%
1.4
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
37.3
12%
3.1
CA
Relevium Technologies Inc
XTSX:RLV
Negative Multiple: -6 373.4 N/A N/A
IN
Dabur India Ltd
NSE:DABUR
31.5
10%
3.2
P/E Multiple
Earnings Growth PEG
JP
Kobayashi Pharmaceutical Co Ltd
TSE:4967
Average P/E: 40.2
118.8
72%
1.6
FR
L'Oreal SA
PAR:OR
30.1
13%
2.3
UK
Unilever PLC
LSE:ULVR
11.2
-6%
N/A
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
37.2
7%
5.3
UK
HALEON PLC
LSE:HLN
18.8
11%
1.7
US
Estee Lauder Companies Inc
NYSE:EL
Negative Multiple: -154.1 N/A N/A
DE
Beiersdorf AG
XETRA:BEI
17.4
6%
2.9
JP
Kao Corp
TSE:4452
22.6
10%
2.3
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
62
18%
3.4
CA
Relevium Technologies Inc
XTSX:RLV
Negative Multiple: -4 624.4 N/A N/A
IN
Dabur India Ltd
NSE:DABUR
43.4
11%
3.9

Market Distribution

Higher than 79% of companies in Japan
Percentile
79th
Based on 5 051 companies
79th percentile
15.4
Low
0.1 — 6.7
Typical Range
6.7 — 12.2
High
12.2 —
Distribution Statistics
Japan
Min 0.1
30th Percentile 6.7
Median 8.7
70th Percentile 12.2
Max 214 699 781.2

Kobayashi Pharmaceutical Co Ltd
Glance View

Market Cap
434.3B JPY
Industry
Consumer products

In the bustling landscape of Japanese business, Kobayashi Pharmaceutical Co., Ltd. stands as an epitome of innovation and tradition. Founded in 1886, this company, steeped in history, has consistently demonstrated a knack for transforming simple consumer needs into thriving business opportunities. Core to its operations is the development, manufacturing, and marketing of consumer healthcare products that subtly blend pharmaceutical expertise with daily convenience. This approach has allowed Kobayashi Pharmaceutical to carve out a distinctive niche, particularly in over-the-counter (OTC) health and personal care products. The company's vast array of products is remarkably diverse, ranging from cooling gel sheets for fevers to herbal medicinal drinks, each crafted with an understanding of consumer pain points and a commitment to well-being. What sets Kobayashi apart in the competitive market is its strategic focus on niche products that serve unmet needs. This laser-sharp business model does more than just bolster its domestic market; it drives its global expansion into key markets in Asia, North America, and Europe. The company's profitability hinges not just on innovation but also on its agile response to the shifting preferences of health-conscious consumers. Driven by a mission to deliver "small but valuable products," Kobayashi’s nimble approach, coupled with an impressive R&D focus, ensures that it remains at the forefront of both consumer satisfaction and shareholder value. Much like a well-crafted Japanese garden, every part of Kobayashi's operation is meticulously designed to function harmoniously, making it a standout player in the global consumer healthcare industry.

Intrinsic Value
5 270.32 JPY
Overvaluation 10%
Intrinsic Value
Price ¥5 842
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett